A comprehensive overview of role of combined myoinositol and D-chiroinositol (40:1 ratio) therapy in the management of PCOS

Polycystic Ovarian Syndrome (PCOS) is one of the most common metabolic and reproductive ailment among reproductive age group women. PCOS patients present with a constellation of signs and symptoms associated with menstrual dysfunction and androgen excess, which significantly impacts quality of life. Women with PCOS is at increased risk of various morbidities, which includes obesity, insulin resistance, type II diabetes mellitus, cardiovascular disease (CVD), infertility, cancer, and psychological disorders. Exact pathophysiology of PCOS is poorly understood although studies have suggested an important role of insulin resistance and/or resultant compensatory hyperinsulinemia. Deficiency in the usage and/or tissue availability of myoinositol (MI) and/or D-chiroinositol (DCI) in PCOS patients could likely lead to insulin resistance typical of this syndrome. Recent studies have demonstrated that combined supplement containing both MI + DCI in their physiological plasma ratio 40:1 is able to improve the endocrine profile, ovarian function and the insulin resistance in PCOS patients. The aim of the present review was to summarize currently available data on the MI+DCI (40:1) combination therapy in PCOS patients.

Abstract licence: CC BY-NC-SA

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.